The dependence of IL-6 depletion effects on Zhx2 expression may explain some of the heterogeneity of early clinical trials in patients with COVID-19 (44–47), since IL-6 depletion is still used in some COVID-19 clinical settings. Here, ZHX2 is linked to COVID-19.